Statins in the Treatment of Acute Ischemic Stroke

Author(s): Fabrizio Montecucco, Alessandra Quercioli, Marisol Mirabelli-Badenier, Giorgio Luciano Viviani, Francois Mach

Journal Name: Current Pharmaceutical Biotechnology

Volume 13 , Issue 1 , 2012

Become EABM
Become Reviewer


3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (also known as statins) are drugs active in the blockade of cholesterol synthesis and thus lowering cholesterol serum levels. Since their discovery, experimental evidence showed that statins strongly reduced atherogenesis and the risk of acute ischemic complications, such as acute myocardial infarction and stroke. More recently, direct anti-atherosclerotic effects of statins (independently of lipid profile improvement) have been also shown, suggesting new potential applications for these drugs in both primary and secondary prevention of acute cardiovascular events. Despite some controversies exist, the use of statins has been shown to improve both incidence and survival in acute ischemic stroke. The molecular mechanisms underlying statin-mediated clinical benefits were recently identified in the reduction of carotid plaque vulnerability and the increase of neuroprotection. In the present review, we will update evidence on the promising results with statins to improve ischemic stroke outcomes

Keywords: Atherosclerosis, inflammation, statin, stroke, treatment, neuroprotection, 3-hydroxy-3-methylglutaryl coenzyme A, lowering cholesterol serum levels, myocardial infarction, anti-atherosclerotic effects of statins, brain ischemic diseases, neurological dysfunction, reversible ischemic neurological deficit, magnetic resonance imaging (MRI)

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Page: [68 - 76]
Pages: 9
DOI: 10.2174/138920112798868737

Article Metrics

PDF: 38